Sellas Life Sciences
SLS
13.66
-1.20
-8.08%
Sellas Life Sciences
US · SLS
#2687 by market cap
Listed 1970
13.66
-1.20
-8.08%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:58
Recent news
-
Company notice
SLS BIO Co: Other Management Information(Voluntary Disclosure) (상장폐지결정 등 효력정지 가처분 신청)OPENDART · 2026/10/26
-
Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Raises Target Price to $30Market Newswire · 2026/7/9
-
Rating change
Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $10Market Newswire · 2026/5/15
-
Company notice
Sims Ltd: Appointment of Tiffany Osias as President of SLSASX · 2026/11/5
-
Rating change
Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Raises Target Price to $10Market Newswire · 2026/3/14
-
Company notice
Solstice Minerals Ltd: Application for quotation of securities - SLSASX · 2026/11/6
-
Rating change
A. G. P. Initiates Sellas Life Sciences(SLS.US) With Buy Rating, Announces Target Price $25Market Newswire · 2026/7/6
-
Rating change
Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $4Market Newswire · 2025/2/22
-
Earnings Flash (SLS) SELLAS Life Sciences Posts Q2 Loss $0.05, Vs. FactSet Est of $0.05 LossMT Newswires · 2026/8/12
-
Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/11/15
-
Rating change
A. G. P. Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $7.5Market Newswire · 2025/11/18
-
Rating change
Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and Maze Therapeutics, Inc. (MAZE)TipRanks · 2025/12/31
-
Rating change
Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $7Market Newswire · 2025/12/31
-
SLS Bio to Be Delisted From KOSDAQ on Nov. 5 Following KRX ReviewMT Newswires · 2026/10/26
-
Company notice
SLS BIO Co: Suspension of Stock Trading (투자자 보호)OPENDART · 2026/10/26
-
Rating change
A. G. P. Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Raises Target Price to $10Market Newswire · 2026/3/20
-
Company notice
Syra Health Corp. | 3: Initial statement of beneficial ownership of securities-10% Owner SLS GROUP LLCSEC · 2023/9/29
-
Rating change
A. G. P. Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $10Market Newswire · 2026/5/13
-
Divergence in Insider Trading Among U.S. Biotech Stocks: ImmunityBio (IBRX.US) Sees Largest Cash-Out, While Sellas (SLS.US) Directors Buy In Before 5-Fold SurgeZhitong Finance · 2026/11/12
-
Company notice
SLS BIO Co: Termination of Suspension of Stock Trading (상장폐지에 따른 정리매매 개시)OPENDART · 2026/10/23
-
Company notice
Sims Ltd: SLS Investor Day PresentationASX · 2026/9/18
-
Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/10/30
-
Company notice
Solstice Minerals Ltd: Application for quotation of securities - SLSASX · 2026/9/14
-
Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/8/20
-
Pre-Market Movement | SLS.US Stock Price Fluctuates Amid Multiple News ItemsMarket Newswire · 2026/6/3
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:58:45 · For reference only, not investment advice and not tailored to your situation.
Sellas Life Sciences discussion 0 comments